TOKYO, Japan & MUNICH, Germany--(BUSINESS WIRE)--Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the European Medicines Agency (EMA) has validated the Type II ...
Malaysia’s National Pharmaceutical Regulatory Agency (NPRA) is preparing to trial new timelines for variation applications to “provide greater clarity and more effective monitoring.” NPRA published ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results